Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
Masitinib selectively targets mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN. Phase 3 study (AB07105) evaluating oral masitinib at 6 mg/kg/day versus placebo in severe asthma uncontrolled by oral corticosteroids (OCS) met its primary endpoint.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: AB1010
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Masitinib is a first in class oral drug in severe asthma, selectively targeting mast cells through inhibition of tyrosine kinases c-Kit, LYN and FYN.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Masitinib
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
Details:
The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
